IPN Ipsen SA

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights

and shares composing the share capital

(in accordance with Article L.233-8 II of the French Commercial Code and

Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)

Market: Euronext Paris

ISIN Code: FR 0010259150

LEI: 549300M6SGDPB4Z94P11

DateTotal number of shares composing the share capitalTotal number of voting rights (1)
31 July 202383,814,526Gross total* of voting rights: 132,133,390
Net total** of voting rights: 131,169,452

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).

* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.

** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.

Attachment



EN
04/08/2023

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young children and adults PFIC is a rare and life-threatening liver disease that affects an estimated 100 children and infants in Japan.1 Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) h...

September 19, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Bylvay® (odévixibat) approuvé au Japon pour le traitement d’une maladi...

Bylvay® (odévixibat) approuvé au Japon pour le traitement d’une maladie rare du foie (CIFP) Bylvay® est le premier inhibiteur du transport iléal des acides biliaires administré une fois par jour à être approuvé comme traitement du prurit associé à la cholestase intra-hépatique familiale progressive (CIFP) au Japon, offrant une option de traitement non chirurgicale pour les nourrissons, les jeunes enfants et les adultes. La CIFP est une pathologie hépatique rare et potentiellement mortelle qui touche environ 100 enfants et nourrissons au Japon1. Paris, France – 19 septembre 25 – Ipsen (Eur...

September 19, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from September 08th to September 12th 2025       Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1108/09/2025FR0010259150300118,30AQEUIPSEN549300M6SGDPB4Z94P1108/09/2025FR0010259150600118,60CCXEIPSEN549300M6SGDPB4Z94P1108/09/2025FR001...

September 16, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2025 Présentation agrégée par jour et par marchéDéclaration des transactions sur actions propres réalisées du 08 Septembre au 12 Septembre 2025       Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marchéIPSEN549300M6SGDPB4Z94P1108/09/2025FR0010259150300118,30AQEUIPSEN549300M6SGDPB4Z94P1108/09/2025FR0010259150600118,60CCXEIP...

September 16, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - August 2025 - Monthly information relative to the total number...

Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 August 2025 83,814,526 ...

September 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch